| scholarly article | Q13442814 |
| P50 | author | Zahid H Siddik | Q95937674 |
| P2093 | author name string | Guangan He | |
| Xiaolei Xie | |||
| P2860 | cites work | gammaH2AX: a sensitive molecular marker of DNA damage and repair | Q37687078 |
| Drug-dependent functionalization of wild-type and mutant p53 in cisplatin-resistant human ovarian tumor cells | Q37706855 | ||
| Transcriptional regulation by p53. | Q37777267 | ||
| Critical review about MDM2 in cancer: Possible role in malignant mesothelioma and implications for treatment | Q38584437 | ||
| The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer | Q38858580 | ||
| Attenuating the p53 Pathway in Human Cancers: Many Means to the Same End. | Q38872379 | ||
| Modulation of the poly (ADP-ribose) polymerase inhibitor response and DNA recombination in breast cancer cells by drugs affecting endogenous wild-type p53. | Q38969425 | ||
| Homologous Recombination Repair Factors Rad51 and BRCA1 Are Necessary for Productive Replication of Human Papillomavirus 31. | Q39605249 | ||
| BRIT1/MCPH1 links chromatin remodelling to DNA damage response. | Q39838062 | ||
| MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin. | Q40244145 | ||
| Impaired homologous recombination DNA repair and enhanced sensitivity to DNA damage in prostate cancer cells exposed to anchorage-independence. | Q40443957 | ||
| Bimodal effects of 1R,2R-diaminocyclohexane(trans-diacetato)(dichloro)platinum(IV) on cell cycle checkpoints | Q40769073 | ||
| DNA damage response to the Mdm2 inhibitor nutlin-3. | Q41888583 | ||
| Recruitment of trimeric proliferating cell nuclear antigen by G1-phase cyclin-dependent kinases following DNA damage with platinum-based antitumour agents | Q41899652 | ||
| Reverse phase protein array identification of triple-negative breast cancer subtypes and comparison with mRNA molecular subtypes | Q42378446 | ||
| CRISPR-Cas9-based target validation for p53-reactivating model compounds. | Q42577802 | ||
| MKP-1 suppresses PARP-1 degradation to mediate cisplatin resistance | Q47163224 | ||
| Double bolt regulation of Rad51 by p53: a role for transcriptional repression | Q53621340 | ||
| Levels of HdmX Expression Dictate the Sensitivity of Normal and Transformed Cells to Nutlin-3 | Q58664384 | ||
| Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management | Q58801181 | ||
| Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition | Q64388338 | ||
| Clinical Overview of MDM2/X-Targeted Therapies | Q26767402 | ||
| Resistance and gain-of-resistance phenotypes in cancers harboring wild-type p53 | Q27006998 | ||
| MDM2 and MDMX: Alone and together in regulation of p53 | Q28611422 | ||
| Functional activation of mutant p53V172F by platinum analogs in cisplatin-resistant human tumor cells is dependent on serine-20 phosphorylation | Q29248201 | ||
| Cisplatin: mode of cytotoxic action and molecular basis of resistance | Q29615385 | ||
| Regulating the p53 pathway: in vitro hypotheses, in vivo veritas | Q29615658 | ||
| Drug combination studies and their synergy quantification using the Chou-Talalay method | Q29617422 | ||
| Transcriptional control of human p53-regulated genes | Q29617650 | ||
| Single cell resolution in vivo imaging of DNA damage following PARP inhibition | Q30650918 | ||
| Genome-wide transcriptome profiling of homologous recombination DNA repair | Q33598112 | ||
| Nutlin-3 protects kidney cells during cisplatin therapy by suppressing Bax/Bak activation | Q33808489 | ||
| A p53-independent role for the MDM2 antagonist Nutlin-3 in DNA damage response initiation | Q33825730 | ||
| MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer | Q33869257 | ||
| Inhibition of cyclin-dependent kinases by p21 | Q34447738 | ||
| Differential contributory roles of nucleotide excision and homologous recombination repair for enhancing cisplatin sensitivity in human ovarian cancer cells | Q34722650 | ||
| Targeting MDM2-p53 interaction for cancer therapy: are we there yet? | Q35030217 | ||
| Pharmacological inhibition of Mdm2 triggers growth arrest and promotes DNA breakage in mouse colon tumors and human colon cancer cells | Q35184378 | ||
| The role of p53 in chemosensitivity and radiosensitivity. | Q35567279 | ||
| CHK1 Inhibition Synergizes with Gemcitabine Initially by Destabilizing the DNA Replication Apparatus. | Q35682592 | ||
| The p53 response to DNA damage | Q35848498 | ||
| Pharmacologically Increasing Mdm2 Inhibits DNA Repair and Cooperates with Genotoxic Agents to Kill p53-Inactivated Ovarian Cancer Cells | Q35977483 | ||
| Recognition and processing of cisplatin- and oxaliplatin-DNA adducts | Q35988488 | ||
| MDM2 and MDM4: p53 regulators as targets in anticancer therapy | Q36094618 | ||
| Overcoming biochemical pharmacologic mechanisms of platinum resistance with a texaphyrin–platinum conjugate | Q36294083 | ||
| DNA-damage repair; the good, the bad, and the ugly | Q36487307 | ||
| p53 modulation of the DNA damage response | Q36619503 | ||
| The impact of S- and G2-checkpoint response on the fidelity of G1-arrest by cisplatin and its comparison to a non-cross-resistant platinum(IV) analog | Q36697283 | ||
| Use of the Rad51 promoter for targeted anti-cancer therapy | Q37081622 | ||
| Heterozygous p53(V172F) mutation in cisplatin-resistant human tumor cells promotes MDM4 recruitment and decreases stability and transactivity of p53. | Q37621428 | ||
| P433 | issue | 4 | |
| P304 | page(s) | 237-249 | |
| P577 | publication date | 2020-02-16 | |
| P1433 | published in | Molecular Pharmacology | Q1943386 |
| P1476 | title | Cisplatin in Combination with MDM2 Inhibition Downregulates Rad51 Recombinase in a Bimodal Manner to Inhibit Homologous Recombination and Augment Tumor Cell Kill | |
| P478 | volume | 97 |
Search more.